OTCM
BDPT
Market cap501kUSD
Jul 16, Last price
0.06USD
1D
-9.18%
1Q
-30.75%
Jan 2017
-99.91%
IPO
-99.99%
Name
BioAdaptives Inc
Chart & Performance
P/E
—
P/S
17.55
EPS
—
Div Yield, %
—
Shrs. gr., 5y
101.16%
Rev. gr., 5y
%
Revenues
29k
+66.31%
Net income
-712k
L-34.04%
CFO
-224k
L-1.53%
Profile
BioAdaptives, Inc. markets and distributes natural plant and algal-based products for humans and animals. The company focuses on offering health and wellness products, such as dietary supplements. It offers PrimiCell, PluriPain, PrimiLungs, PrimiLive, and PrimiSleep, as well as markets Lung Flute for humans; Canine Regen and Equine Regen for dogs and horses, as well as base formulations, including Equine All-in-One to trainers, horse owners and boarding stables; and All-in-One products, which combine minerals, vitamins, amino acids, and other botanicals with the Regen compounds. The company was formerly known as APEX 8 Inc. and changed its name to BioAdaptives, Inc. in September 2013. BioAdaptives, Inc. was incorporated in 2013 and is based in Las Vegas, Nevada.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 29 66.31% | 17 -13.15% | |||||||
Cost of revenue | 229 | 377 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (201) | (360) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 185 | ||||||||
Tax Rate | |||||||||
NOPAT | (201) | (544) | |||||||
Net income | (712) -34.04% | (1,080) -18.32% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 178 | 522 | |||||||
BB yield | -63.71% | -820.16% | |||||||
| Debt | |||||||||
Debt current | 329 | 392 | |||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | 399 | ||||||||
Net debt | 268 | 367 | |||||||
| Cash flow | |||||||||
Cash from operating activities | (224) | (227) | |||||||
CAPEX | |||||||||
Cash from investing activities | 148 | ||||||||
Cash from financing activities | 259 | 170 | |||||||
FCF | 70 | (198) | |||||||
| Balance | |||||||||
Cash | 61 | 25 | |||||||
Long term investments | |||||||||
Excess cash | 59 | 25 | |||||||
Stockholders' equity | (8,175) | (7,526) | |||||||
Invested Capital | 6,857 | 6,467 | |||||||
ROIC | |||||||||
ROCE | 15.24% | 33.96% | |||||||
| EV | |||||||||
Common stock shares outstanding | 559,069 | 106,011 | |||||||
Price | 0.00 -16.67% | 0.00 -94.00% | |||||||
Market cap | 280 339.47% | 64 -81.15% | |||||||
EV | 548 | 430 | |||||||
EBITDA | (173) | (298) | |||||||
EV/EBITDA | |||||||||
Interest | 163 | 289 | |||||||
Interest/NOPBT | |||||||||